2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1100

Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1135

Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1001

Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1740

Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1609

Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1310

Osteoarthritis: What’s in a Name?

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1295

Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 1138

Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1208

Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1587

Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1053

Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1462

Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1380

Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1350

Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1196

Patient Preference for an Electronic MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/ Routine Assessment of Patient Index Data), Which Gives Similar Results Compared to a Paper Version

Measures Of Healthcare Quality Poster II: Improving Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].